RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) INHIBITORS IN THE TREATMENT OF PANCREATIC DUCTAL CARCINOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 11, 2024
app pub date -
Jan 10, 2023
filing date -
Jan 10, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Embodiments provide for methods of treatment for subjects suffering from a condition/disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully